Lung Therapeutics is a biopharmaceutical company developing medicines for unmet medical needs in fibrosis and lung disease. Its two lead drug candidates are LTI-01, a pro-enzyme for the treatment of loculated pleural effusion (LPE), and LTI-03, a peptide drug targeting the survival of lung epithelial cells and the inhibition of the negative effects of fibroblast proliferation in idiopathic pulmonary fibrosis patients.